<DOC>
	<DOCNO>NCT00696423</DOCNO>
	<brief_summary>This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00412854 ) . This Phase IIIB study compare GSK Biologicals ' DTPa/Hib vaccine separately administer DTPa Hib vaccines Chinese child 18 24 month age , term safety immunogenicity .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' Infanrix/Hib Children</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . Subjects complete full threedose primary vaccination course study 104567 . A male female child , include , 18 24 month age time booster vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede booster vaccination , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period , exception measles combine measles , mumps rubella ( MMR ) vaccination . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous booster vaccination diphtheria , tetanus , pertussis and/or Haemophilus influenzae type b disease since end primary study . History diphtheria , tetanus , pertussis and/or Haemophilus influenzae type b disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History progressive neurological disorder seizure . Acute disease and/or fever time enrolment . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period . Occurrence follow adverse event ( AEs ) previous administration diphtheriatetanuspertussis ( DTP ) vaccine : Hypersensitivity reaction due component vaccine . Encephalopathy . Fever ≥ 40.0 °C ( axillary temperature ) within 48 hour vaccination . Collapse shocklike state within 48 hour vaccination . Persistent , inconsolable cry occur within 48 hour vaccination last ≥ 3 hour . Seizures without fever occur within 3 day vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Infanrix/Hib</keyword>
	<keyword>Chinese child</keyword>
</DOC>